Pharmacokinetics of a new orodispersible tablet formulation of vardenafil: Results of three clinical trials

Clinical Drug Investigation

Volumn 31, Issue 1, 2011, Pages 27-41

  Heinig, Roland ^a   Weimann, Boris ^b   Dietrich, Hartmut ^c   Böttcher, Michael Friedrich ^a  

^a BAYER PHARMA AG   (Germany)

^b Chrestos Concept GmbH and Co KG   (Germany)

^c MEDA Manufacturing GmbH   (Germany)

Author keywords

, therapeutic use; , treatment; Erectile dysfunction; Type 5 cyclic nucleotide phosphodiesterase inhibitors; Vardenafil

Indexed keywords

DRUG METABOLITE; N NORVARDENAFIL; PLACEBO; UNCLASSIFIED DRUG; VARDENAFIL; WATER;

AGE DISTRIBUTION; AREA UNDER THE CURVE; ARTICLE; CALORIC INTAKE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; FILM COATING; FLUID INTAKE; FLUSHING; FOOD INTAKE; HUMAN; LIPID DIET; MAXIMUM PLASMA CONCENTRATION; NOSE CONGESTION; ORODISPERSIBLE TABLET; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SIDE EFFECT; TABLET FORMULATION; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PIPERAZINES; SULFONES; TABLETS; TRIAZINES;

EID: 78149376867     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/11584950-000000000-00000     Document Type: Article

References (32)

1. Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol 2005 Jul; 174 (1): 230-9
2. Wespes E, Amar E, Hatzichristou D, et al. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006 May; 49 (5): 806-15
3. Eardley I, Lee JC, Shabsigh R, et al. Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications. J Sex Med 2010 Jan; 7 (1 Pt 1): 244-55
4. Edwards D, Hackett G, Collins O, et al. Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): a randomized, doubleblind, placebo-controlled trial in PDE5 inhibitor-naive men with ED and their partners. J Sex Med 2006 Nov; 3 (6): 1028-36
5. Fisher WA, Rosen RC, Mollen M, et al. Improving the sexual quality of life of couples affected by erectile dysfunction: a double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med 2005 Sep; 2 (5): 699-708
6. Giuliano F, Rubio-Aurioles E, Kennelly M, et al. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Neurology 2006 Jan 24; 66 (2): 210-6
7. Hatzichristou D, Montorsi F, Buvat J, et al. The efficacy and safety of flexible-dose vardenafil (Levitra®) in a broad population of European men. Eur Urol 2004May; 45 (5): 634-41; discussion 41
8. Hellstrom WJ, Gittelman M, Karlin G, et al. Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002 Nov-Dec; 23 (6): 763-71
9. Ralph D, Eardley I, Kell P, et al. Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. BJU Int 2007 Jul; 100 (1): 130-6
10. Rosen R, Shabsigh R, Berber M, et al. Efficacy and tolerability of vardenafil in men with mild depression and erectile dysfunction: the depression-related improvement with vardenafil for erectile response study. Am J Psychiatry 2006 Jan; 163 (1): 79-87
11. Stief C, Porst H, Saenz De Tejada I, et al. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 2004 Mar; 58 (3): 230-9
12. Berry B, Altman P, Rowe J, et al. Comparison of pharmacokinetics of vardenafil administered using an ultrasonic nebulizer for inhalation vs. a single 10-mg oral tablet. J Sex Med. Epub 2009 Jul 28
13. Bischoff E. Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events. Int J Impot Res 2004 Jun; 16 Suppl. 1: S34-7
14. Levitra® (vardenafil HCl) [package insert]. Wayne (NJ): Bayer HealthCare Pharmaceuticals Inc., 2008
15. Data on file, Bayer Schering, Apr 7, 2008
16. Data on file, Bayer Schering, May 28, 2009
17. Sperling H, Debruyne F, Boermans A, et al. The POTENT I randomized trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J Sex Med 2010 Mar 3; 7 (4 Pt 1): 1497-507
18. Center for Drug Evaluation and Research (CDER). Guidance for industry: food-effect bioavailability and fed bioequivalence studies, 2002 [online]. Available from URL:http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm070241.pdf [Accessed 2010 Feb 2]
19. NIH Consensus Conference. Impotence: NIH consensus development panel on impotence. JAMA 1993 Jul 7; 270 (1): 83-90
20. Center for Drug Evaluation and Research (CDER). Guidance for industry: bioanalytical method validation, 2001 [online]. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM070107.pdf [Accessed 2010 Feb 2]
21. Data on file, Bayer Schering, May 23, 2000
22. Data on file, Bayer Schering, Jun 20, 2001
23. European Pharmacopeia, 6th ed. Strasbourg: Council of Europe, European Directorate for the Quality of Medicines, 2007
24. United States Pharmacopeia. USP 28 physical tests <701> disintegration [online]. Available from URL: http://www.usp.org/pdf/EN/USPNF/ chapter701.pdf [Accessed 2010 Sep 19]
25. Percival RS, Challacombe SJ, Marsh PD. Flow rates of resting whole and stimulated parotid saliva in relation to age and gender. J Dent Res 1994 Aug; 73 (8): 1416-20
26. Gittelman M, McMahon CG, Rodríguez-Rivera JA, et al. The POTENT II randomised trial: efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int J Clin Pract 2010; 64 (5): 594-603
27. Donatucci C, Eardley I, Buvat J, et al. Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification. J SexMed 2004 Nov; 1 (3): 301-9
28. Hellstrom WJ, Gittelman M, Karlin G, et al. Sustained efficacy and tolerability of vardenafil, a highly potent selective phosphodiesterase type 5 inhibitor, in men with erectile dysfunction: results of a randomized, double-blind, 26-week placebo-controlled pivotal trial. Urology 2003 Apr; 61 (4 Suppl. 1): 8-14
29. Rajagopalan P, Mazzu A, Xia C, et al. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003 Mar; 43 (3): 260-7
30. Mehrotra N, Gupta M, Kovar A, et al. The role of pharmacokinetics and pharmacodynamics in phosphodiesterase-5 inhibitor therapy. Int J Impot Res 2007 May-Jun; 19 (3): 253-64
31. Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev 2009; 41 (2): 67-76
32. Raheem AA, Kell P. Patient preference and satisfaction in erectile dysfunction therapy: a comparison of the three phosphodiesterase-5 inhibitors sildenafil, vardenafil and tadalafil. Patient Prefer Adherence 2009; 3: 99-104